Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody. In return ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a treatment for HER2-positive non-small cell lung cancer (NSCLC), tumour shrinkage ...

After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well. Boehringer will pay AimedBio up to $991 million to license and develop ...

With a new president of U.S. pharma at the helm—and two key FDA approvals now in the books—Boehringer Ingelheim is sharpening its focus on the lucrative American market. In this week’s episode of “The ...

Boehringer Ingelheim is unveiling a new direct-to-consumer platform, Boehringer Ingelheim Access. The platform will offer a convenient way for patients to order and receive home delivery of select ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

Boehringer Ingelheim today announced the launch of its new direct-to-consumer platform, “Boehringer Ingelheim Access.” The platform will offer a convenient way for patients in the U.S. to order and ...

Boehringer Ingelheim GmbH won approval in the US for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company. The drug, ...

Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology ...

Objective: This study aimed to describe the technique and evaluate the clinical outcomes of utilizing a biportal endoscopic spine surgery (BESS) for the treatment of thoracolumbar intervertebral disc ...

New MoU positions UAE as rising global hub for pharmaceutical innovation Abu Dhabi: As part of its broader vision to position the UAE as a regional and global hub for life sciences, health innovation, ...